Xin Lang Cai Jing·2025-11-20 07:38Core Viewpoint - Haiprime, a leading multinational pharmaceutical company, is benefiting from the depreciation of the RMB and has a strong focus on the heparin industry chain, biopharmaceutical CDMO, and innovative drug development [2][3]. Company Overview - Haiprime was established in 1998 in Shenzhen and has both A and H share financing platforms. The company aims to provide high-quality, safe, and effective drugs and services to global patients [2]. - The main business segments of Haiprime include heparin raw materials, low molecular weight heparin products, and biopharmaceutical CDMO services [7]. Financial Performance - For the period from January to September 2025, Haiprime achieved a revenue of 4.194 billion yuan, representing a year-on-year growth of 3.09%. However, the net profit attributable to shareholders decreased by 29.04% to 554 million yuan [7]. - As of September 30, 2025, the overseas revenue accounted for 93.04% of total revenue, benefiting from the depreciation of the RMB [3]. Shareholder Information - As of September 30, 2025, Haiprime had 27,000 shareholders, an increase of 2.60% from the previous period. The average number of circulating shares per person remained at zero [7]. - The company has distributed a total of 4.21 billion yuan in dividends since its A-share listing, with 514 million yuan distributed over the past three years [8]. Market Activity - On November 20, Haiprime's stock price increased by 0.42%, with a trading volume of 39.2348 million yuan and a turnover rate of 0.26%. The total market capitalization reached 17.71 billion yuan [1].